D&A at other companies
Other financials
Where this comes from
Reported directly by NewAmsterdam Pharma Company in its filing.
Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.
The official record: NewAmsterdam Pharma Company’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about NewAmsterdam Pharma Company's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is NewAmsterdam Pharma Company's D&A?
- NewAmsterdam Pharma Company (NAMS) reported D&A of $62K in Q1 2026.
- How has NewAmsterdam Pharma Company's D&A changed year-over-year?
- NewAmsterdam Pharma Company's D&A increased by 19.2% year-over-year, from $52K to $62K.
- What is the long-term trend for NewAmsterdam Pharma Company's D&A?
- Over 4 years (2021 to 2025), NewAmsterdam Pharma Company's D&A has grown at a 157.6% compound annual growth rate (CAGR), from $5K to $220K.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.